OverviewSuggest Edit

Xencor is a clinical-stage biopharmaceutical company which focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The Company's product candidates include immune inhibitors for the treatment of autoimmune diseases, asthma and allergic diseases, acute myeloid leukemia, B-cell malignancies, non-Hodgkin lymphomas and chronic lymphocytic leukemia and multiple myeloma.

TypePublic
Founded1997
HQMonrovia, US
Websitexencor.com

Latest Updates

Employees (est.) (Dec 2019)166(+7%)
Job Openings19
Revenue (FY, 2019)$156.7 M(+286%)
Share Price (Sept 2020)$37.7 (-2%)
Cybersecurity ratingAMore

Key People/Management at Xencor

John R. Desjarlais

John R. Desjarlais

Senior Vice President, Research & Chief Scientific Officer
Bassil I. Dahiyat

Bassil I. Dahiyat

President & Chief Executive Officer, Director
Ellen G. Feigal

Ellen G. Feigal

Director
John J. Kuch

John J. Kuch

Senior Vice President & Chief Financial Officer
Kevin Gorman

Kevin Gorman

Director
Kurt Gustafson

Kurt Gustafson

Director
Show more

Xencor Office Locations

Xencor has offices in Monrovia and San Diego
Monrovia, US (HQ)
111 W Lemon Ave
San Diego, US
12481 High Bluff Dr #200
Show all (2)

Xencor Financials and Metrics

Xencor Revenue

Xencor's revenue was reported to be $156.70 m in FY, 2019
USD

Revenue (Q2, 2020)

13.1m

Net income (Q2, 2020)

(35.0m)

EBIT (Q2, 2020)

(37.6m)

Market capitalization (23-Sept-2020)

2.2b

Closing stock price (23-Sept-2020)

37.7

Cash (30-Jun-2020)

109.5m

EV

2.1b
Xencor's current market capitalization is $2.2 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

40.6m156.7m

General and administrative expense

7.5m12.0m13.1m17.5m22.5m24.3m

R&D expense

18.5m34.1m51.9m71.8m97.5m118.6m

Operating expense total

26.0m46.1m65.0m89.3m120.0m142.9m
Quarterly
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

29.0m111.9m19.5m21.8m32.4m13.1m

General and administrative expense

1.6m2.2m2.5m3.2m4.0m3.0m3.0m4.8m4.1m4.2m4.6m5.0m7.4m5.5m5.8m6.3m7.2m7.2m

R&D expense

4.3m5.0m7.5m10.6m10.0m14.4m14.1m15.0m16.9m19.4m26.1m23.3m21.0m28.2m33.3m29.8m33.9m43.5m

Operating expense total

5.9m7.1m10.0m13.8m14.0m17.5m17.1m19.9m21.0m23.6m30.6m28.3m28.4m33.7m39.1m36.0m41.2m50.7m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(16.4m)(17.6m)23.6m(48.9m)(70.4m)26.9m

Depreciation and Amortization

882.0k1.1m1.5m2.0m3.3m4.3m

Accounts Payable

(943.0k)4.7m(2.5m)3.0m(3.1m)6.4m

Cash From Operating Activities

(21.4m)26.7m94.6m(33.7m)(79.8m)64.4m
USDQ1, 2014

Financial Leverage

1.2 x
Show all financial metrics

Xencor Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Xencor Online and Social Media Presence

Embed Graph

Xencor News and Updates

Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D.

Dr. Foster’s career spans 35 years in academic research, medical practice and industry leadership. For ten years, he has led Xencor’s clinical development strategy, as both chief medical officer and as a consultant in a substantially similar capacity. Xencor has initiated an executive search for a s…

Xencor Reports Fourth Quarter and Full Year 2018 Financial Results

MONROVIA, Calif., Feb. 25, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for the...

Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech

MONROVIA, Calif., Feb. 5, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today announced it has entered into a...

Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting

MONROVIA, Calif., Dec. 3, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced initial data from its ongoing Phase 1...

Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference

MONROVIA, Calif., Nov. 20, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat,...

Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors

MONROVIA, Calif., Nov. 8, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced the appointment of Ellen G....
Show more

Xencor Blogs

Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 8, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc.

Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

MONROVIA, Calif. --(BUSINESS WIRE)--Jun. 22, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new preclinical data from three XmAb ® 2+1

Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

MONROVIA, Calif. --(BUSINESS WIRE)--May 15, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will present new preclinical data on three XmAb ® 2+1

Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors

Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors Content Import Wed, 05/13/2020 - 17:00 Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid …

Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors

-- XmAb20717 generally well-tolerated and a confirmed complete response (CR) observed at highest dose level tested -- -- Robust, dose-dependent immune activation consistent with inhibition of both PD-1 and CTLA-4 checkpoints -- -- Further dose-escalation and expansion cohorts continue to enroll

Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

MONROVIA, Calif. --(BUSINESS WIRE)--May 13, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief executive
Show more

Xencor Frequently Asked Questions

  • When was Xencor founded?

    Xencor was founded in 1997.

  • Who are Xencor key executives?

    Xencor's key executives are John R. Desjarlais, Bassil I. Dahiyat and Ellen G. Feigal.

  • How many employees does Xencor have?

    Xencor has 166 employees.

  • What is Xencor revenue?

    Latest Xencor annual revenue is $156.7 m.

  • What is Xencor revenue per employee?

    Latest Xencor revenue per employee is $944 k.

  • Who are Xencor competitors?

    Competitors of Xencor include NOXXON Pharma, PLUS THERAPEUTICS and ASLAN Pharmaceuticals.

  • Where is Xencor headquarters?

    Xencor headquarters is located at 111 W Lemon Ave, Monrovia.

  • Where are Xencor offices?

    Xencor has offices in Monrovia and San Diego.

  • How many offices does Xencor have?

    Xencor has 2 offices.